Annexon Company Insiders
| ANNX Stock | USD 2.81 0.34 13.77% |
Annexon employs about 106 people. The company is managed by 16 executives with a total tenure of roughly 248 years, averaging almost 15.0 years of service per executive, having 6.63 employees per reported executive. Break down of Annexon's management performance can provide insight into the company performance.
Annexon Management Team Effectiveness
The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6613) %, meaning that it created substantial loss on money invested by shareholders. Annexon's management efficiency ratios could be used to measure how well Annexon manages its routine affairs as well as how well it operates its assets and liabilities.Annexon Workforce Comparison
Annexon is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 414,334. Annexon adds roughly 106 in number of employees claiming only tiny portion of equities under Health Care industry.
Annexon Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annexon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annexon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Annexon insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ted Yednock over a week ago Disposition of 1783 shares by Ted Yednock of Annexon at 2.99 subject to Rule 16b-3 | ||
Cockroft Bettina M. over three weeks ago Acquisition by Cockroft Bettina M. of 55000 shares of Annexon at 2.55 subject to Rule 16b-3 | ||
Ted Yednock over three months ago Acquisition by Ted Yednock of 272575 shares of Annexon at 2.5 subject to Rule 16b-3 | ||
Jones William A Jr over three months ago Insider Trading | ||
Love Douglas over three months ago Disposition of 37994 shares by Love Douglas of Annexon at 1.4096 subject to Rule 16b-3 | ||
Carson William H. over six months ago Acquisition by Carson William H. of 24000 shares of Annexon at 2.88 subject to Rule 16b-3 | ||
Carson William H. over six months ago Acquisition by Carson William H. of 3200 shares of Annexon at 5.33 subject to Rule 16b-3 | ||
Love Douglas over six months ago Disposition of 36050 shares by Love Douglas of Annexon at 1.8501 subject to Rule 16b-3 |
Annexon Notable Stakeholders
An Annexon stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Annexon often face trade-offs trying to please all of them. Annexon's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Annexon's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JD Esq | President CEO | Profile | |
| Jennifer CPA | CFO VP | Profile | |
| Dean Artis | Chief VP | Profile | |
| Shikhar MBA | Senior Commercial | Profile | |
| Arnon Rosenthal | Founder | Profile | |
| Michael MBA | Executive Officer | Profile | |
| Lloyd MD | Senior Innovation | Profile | |
| Mirella Toro | Sec | Profile | |
| Ted Yednock | Chief VP | Profile | |
| HenkAndre MD | Senior Medicine | Profile | |
| Jamie MD | Executive Officer | Profile | |
| Esq JD | Pres CEO | Profile | |
| Larry Mattheakis | Ex Officer | Profile | |
| Jennifer Lew | Ex CFO | Profile | |
| Miriam Mason | Senior Communications | Profile | |
| Sunil PharmD | Senior Affairs | Profile |
About Annexon Management Performance
The success or failure of an entity such as Annexon often depends on how effective the management is. Annexon management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Annexon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Annexon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company was incorporated in 2011 and is headquartered in Brisbane, California. Annexon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 75 people.
Please note, the imprecision that can be found in Annexon's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annexon. Check Annexon's Beneish M Score to see the likelihood of Annexon's management manipulating its earnings.
Annexon Workforce Analysis
Traditionally, organizations such as Annexon use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Annexon within its industry.Annexon Manpower Efficiency
Return on Annexon Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 8.6M | |
| Working Capital Per Employee | 2.7M | |
| Working Capital Per Executive | 17.9M |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.